A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

被引：22

作者：

Watts, Justin M. ^{[1
]}

Bradley, Terrence J. ^{[1
]}

Thomassen, Amber ^{[2
]}

Brunner, Andrew M. ^{[3
]}

Minden, Mark D. ^{[4
]}

Papadantonakis, Nikolaos ^{[5
]}

Abedin, Sameem ^{[6
]}

Baines, Amanda J. ^{[7
]}

Barbash, Olena ^{[8
]}

Gorman, Shelby ^{[8
]}

Kremer, Brandon E. ^{[8
]}

Borthakur, Gautam M. ^{[9
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[2] Univ Miami, Sylvester Canc Ctr, Miami, FL USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Univ Hlth Network, Dept Med Oncol & Hematol, Leukemia Program, Princess Margaret Canc Ctr, Toronto, ON, Canada

[5] Taussig Canc Inst, Birmingham, AL USA

[6] Northwestern Mem Hosp, McGaw Med Ctr, Milwaukee, WI USA

[7] GlaxoSmithKline, Stevenage, Herts, England

[8] GlaxoSmithKline, Collegeville, PA USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-130337

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2656

引用

页数：4

共 50 条

[31] A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors
Yu, J.
Sun, Y.
Guo, S.
Wang, H. Q.
Wu, J.
Jiang, X.
Chen, J.
Yang, G.
Yang, C.
ANNALS OF ONCOLOGY, 2023, 34 : S474 - S474
[32] Phase I/II study of vosaroxin and decitabine in older patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Daver, Naval Guastad
Kantarjian, Hagop M.
Pierce, Sherry
Brandt, Mark
Dinardo, Courtney Denton
Pemmaraju, Naveen
Vaughan, Kenneth
Garcia-Manero, Guillermo
Jabbour, Elias
Borthakur, Gautam
Kadia, Tapan M.
Cortes, Jorge E.
Craig, Adam
Ravandi, Farhad
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[33] A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies
Patel, Manish R.
Monga, Varun
Jauhari, Shekeab
Stevens, Don
Masarova, Lucia
McKean, Meredith
Mauro, David
Viscusi, John
Scherle, Peggy
Bhagwat, Neha
Moore, Andrew
Sun, William
Chiaverelli, Rachel
Mintah, Eric
Nath, Rajneesh
Stein, Eytan M.
Palmisiano, Neil
Sutamtewagul, Grerk
Verstovsek, Srdan
BLOOD, 2021, 138
[34] Update of a phase I study of sorafenib in patients with refractory/relapsed acute myeloid leukemia or high-risk myelodysplastic syndrome
Delmonte, John, Jr.
Kantarjian, Hagop M.
Andreef, Michael
Faderl, Stefan
Wright, John J.
Zhang, Weiguo
Konopleva, Marina
Verstovsek, Srdan
Borthakur, Gautam
Ravandi, Farhad
Cortes, Jorge
BLOOD, 2007, 110 (11) : 272A - 273A
[35] Final update of phase I-II study of the farnesyltransferase inhibitor tipifarnib in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Delmonte, John, Jr.
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Estrov, Zeev
Ravandi, Farhad
Verstovsek, Srdan
O'Brien, Susan
Koller, Charles A.
Faderl, Stefan
Thomas, Deborah A.
Wright, John J.
Cortes, Jorge
BLOOD, 2007, 110 (11) : 136A - 136A
[36] A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium
Silverman, L. R.
Verma, A.
Odchimar-Reissig, R.
Cozza, A.
Najfeld, V.
Licht, J. D.
Zwiebel, J. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[37] PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies
Kim, Tae Min
Lewis, Katharine L.
Alderuccio, Juan Pablo
Lee, Hun Ju
Derenzini, Enrico
Zinzani, Pier Luigi
Ladetto, Marco
Ghesquieres, Herve
Phillips, Elizabeth H.
Lemonnier, Francois
Morschhauser, Franck
Balari, Ana Sureda
Izquierdo, Antonia Rodriguez
Borchmann, Peter
Weinstock, Matthew
Svoboda, Jakub
Dean, Emma
Urosevic, Jelena
Meyer, Stefanie
Chen, Robert
Olsson, Richard
Beyfuss, Kaitlyn
Collins, Graham P.
BLOOD, 2024, 144 : 16742 - 16743
[38] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Naval, Daver
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Pemmaraju, Naveen
Kadia, Tapan M.
DiNardo, Courtney D.
Jain, Nitin
Borthakur, Gautam
Jabbour, Elias
Konopleva, Marina
Cortes, Jorge E.
Craig, Adam
Ravandi, Farhad
BLOOD, 2014, 124 (21)
[39] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
DiNardo, Courtney D.
Daver, Naval
Jabbour, Elias
Kadia, Tapan
Borthakur, Gautam
Konopleva, Marina
Pemmaraju, Naveen
Yang, Hui
Wei, Yue
Wierda, William G.
Bueso-Ramos, Carlos E.
Patel, Keyur P.
Cortes, Jorge E.
Ravandi, Farhad
Kantarjian, Hagop
Garcia-Manero, Guillermo
BLOOD, 2014, 124 (21)
[40] Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD1152, in Patients with Advanced Acute Myeloid Leukemia
Lowenberg, Bob
Rousselot, Philippe
Martinelli, Giovanni
Goudie, Alison
Stockman, Paul
Kantarjian, Hagop
BLOOD, 2009, 114 (22) : 821 - 821

← 1 2 3 4 5 →